The earnings call highlighted strong sequential revenue growth, successful international expansion, and a robust cash position, indicating positive forward momentum. However, year-over-year revenue decline and decreased adjusted EBITDA present concerns, although these may be offset by promising innovations and clinical study results.

Company Guidance

During Covalon's Q3 Fiscal 2025 conference call, CEO Brent Ashton provided optimistic guidance, emphasizing key financial and operational metrics. The company reported $8.4 million in revenue for Q3, marking a sequential increase of over 10% from Q2, driven by more than 40% growth in its U.S. advanced wound care sales. Despite a year-over-year revenue decline of 9% for Q3, the company achieved an adjusted EBITDA of nearly $1 million, reflecting a 50% increase from the previous quarter. Ashton highlighted a robust 13% growth in trailing 12-month revenue and a 27% compounded annual growth rate over three years, illustrating Covalon's market success. Additionally, the company maintained a strong cash position of over $18 million, up almost $9 million from the previous year. Operationally, Covalon achieved 100% retention of its top 50 U.S. hospital customers and added 15 new hospital accounts in Q3, with a total of 65 new accounts for the year. Ashton also shared promising updates on the company's innovation pipeline and international market expansion, including new product registrations and distribution agreements.

Sequential Revenue Growth

Revenue at $8.4 million was up more than 10% sequentially between Q3 and Q2, led by more than 40% sequential quarterly growth in the U.S. advanced wound care sales channel.

International Expansion

Successfully registered VALGuard product in Canada, Brazil, and Panama, along with a new distribution agreement in Israel and a tender for IV Clear in India.

Strong Cash Position

Cash position at over $18 million, up almost $9 million from a year ago, with cash on hand growing each of the past 5 quarters.

Innovation and New Use Cases

Introduction of new use case for CovaClear IV, generating interest and offering cost savings, with potential for significant market expansion.

Positive Clinical Study Results

Study on VALGuard product showed significant reduction in bloodstream infection rates, published in the Journal of the Association for Vascular Access.

Covalon Technologies (TSE:COV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:COV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 22, 2026	2025 (Q4)	- / -	0.04	―	―	―
Aug 21, 2025	2025 (Q3)	0.04 / 0.00	0.059	―	―	―
May 28, 2025	2025 (Q2)	0.01 / 0.02	0.059	-66.10% (-0.04)	―	―
Feb 21, 2025	2025 (Q1)	- / -	-0.034	―	―	―
Jan 07, 2025	2024 (Q4)	-0.03 / 0.04	-0.034	217.65% (+0.07)	―	―
Aug 21, 2024	2024 (Q3)	- / 0.06	-0.02	395.00% (+0.08)	―	―
May 29, 2024	2024 (Q2)	- / 0.06	-0.028	310.71% (+0.09)	―	―
Feb 28, 2024	2024 (Q1)	- / -	-0.015	―	―	―
Jan 26, 2024	2023 (Q4)	- / -0.03	-0.015	-126.67% (-0.02)	―	―
Aug 16, 2023	2023 (Q3)	- / -0.02	-0.062	67.74% (+0.04)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:COV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 21, 2025	C$2.88	C$2.40	-16.67%
May 28, 2025	C$2.80	C$2.57	-8.21%
Feb 21, 2025	C$3.18	C$2.80	-11.95%
Jan 07, 2025	C$3.59	C$3.29	-8.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Covalon Technologies Ltd (TSE:COV) report earnings?

Covalon Technologies Ltd (TSE:COV) is schdueled to report earning on Jan 22, 2026, TBA (Confirmed).

What is Covalon Technologies Ltd (TSE:COV) earnings time?

Covalon Technologies Ltd (TSE:COV) earnings time is at Jan 22, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:COV EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing